CHURCH KEVIN 4
4 · LeonaBio, Inc. · Filed Apr 13, 2026
Research Summary
AI-generated summary of this filing
LeonaBio (LONA) CSO Kevin Church Receives 300,000-Share Award
What Happened
Kevin Church, Chief Scientific Officer of LeonaBio, was granted derivative awards covering 300,000 shares on 2026-04-09. The filing reports an acquisition amount of 300,000 shares at $0.00 (reported value $0), indicating a grant of equity-linked awards (e.g., stock options or restricted stock units) rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-04-09 (Grant/Award, code A)
- Reported price/consideration: $0.00 (reported acquisition value $0)
- Vesting: Shares subject to the award vest monthly over 48 months, subject to continued service (footnote F1).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Filing date: 2026-04-13 (filed within the Form 4 two-business-day reporting window).
- Nature: Derivative award — this is a grant of rights to equity, not an immediate cash transaction or sale.
Context
Equity awards to executives are common compensation tools and do not reflect an immediate purchase or sale in the market. Because these awards vest over time, they provide a service-conditional incentive rather than a current change in open-market holdings. Retail investors should view this as routine executive compensation unless combined with other insider buying or selling activity.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-04-09+300,000→ 300,000 totalExercise: $9.54Exp: 2036-04-08→ Common Stock (300,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.